Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis

Table 2 Patient characteristics of included studies

Ref.	Patient Number (Api)	Patient Number (Riv)	Patient Number (Dab)	Patient Number (War)	Age (Api)	Age (Riv)	Age (Dab)	Age (War)	HAS-BLED (Api)	HAS-BLED (Riv)	HAS-BLED (Dab)	HAS-BLED (War)	CHA2DS2-VASc (Api)	CHA2DS2-VASc (Riv)	CHA2DS2-VASc (Dab)	CHA2DS2-VASc (War)
Chan et al[25], 2016	N/A	N/A	9940	9913	N/A	N/A	75 ± 10	76 ± 10	N/A	N/A	2.57 ± 1.01	2.58 ± 1.06	N/A	N/A	4.13 ± 1.59	4.16 ± 1.75
Yap et al[26], 2016	N/A	N/A	500	500	N/A	N/A	65.3 ± 11.3	66.8 ± 11.3	N/A	N/A	1.57 ± 0.96	1.67 ± 0.94	N/A	N/A	2.69 ± 1.54	3.40 ± 1.54
Cha et al[27], 2017	2189	5681	3741	23222	70.3 ± 10.0	70.5 ± 9.9	69.3 ± 10.0	68.82 ± 11.1	N/A	N/A	N/A	N/A	3.57 ± 1.29	3.60 ± 1.32	3.51 ± 1.28	3.57 ± 1.31
Kohsaka et al[28], 2017	5977	5090	6726	6726 (War-Dab matched); 5090 (War-Riv matched); 5977 (War-Api matched)	77.4 ± 10.0	75.8 ± 10.0	73.1 ± 9.9	73.3 ± 10.5 (War-Dab matched); 76.2 ± 10.5 (War-Riv matched); 77.7 ± 10.0 (War-Api matched)	N/A	N/A	N/A	N/A	3.5 ± 1.6	3.3 ± 1.6	3.0 ± 1.6	3.0 ± 1.6 (War-Dab matched); 3.4 ± 1.6 (War-Riv matched); 3.5 ± 1.5 (War-Api matched)
Chan et al[29], 2018	5843	27777	20079	19375	76 ± 10	76 ± 10	76 ± 10	76 ± 10	2.96 ± 1.12	2.96 ± 0.51	2.96 ± 0.59	2.97 ± 0.61	3.89 ± 1.56	3.89 ± 0.71	3.88 ± 0.82	3.89 ± 0.88
Huang et al[30], 2018	N/A	9637	N/A	9637	N/A	75.2 ± 10.24	N/A	74.98 ± 10.6	N/A	2.21 ± 1.46	N/A	2.33 ± 1.49	N/A	4.02 ± 1.92	N/A	4.11 ± 2
Okumura et al[31], 2018	428	761	456	1561	73.2 ± 10.1	71.5 ± 9.1	70.9 ± 9.5	72.2 ± 9.3	1.42 ± 0.81	1.32 ± 0.77	1.07 ± 0.71	1.61 ± 0.88	3.12 ± 1.47	2.87 ± 1.45	2.83 ± 1.46	3.08 ± 1.51
Koretsune et al[32], 2018	N/A	N/A	4606	4606	N/A	N/A	74 ± 10	73 ± 11	N/A	N/A	2.1 ± 1.0	2.1 ± 1.1	N/A	N/A	3.3 ± 1.7	3.3 ± 1.7
Chan et al[33], 2019	9952	33022	22371	19761	76 ± 10.5	75.3 ± 10.6	74.2 ± 10.4	70.6 ± 13.4	2.9 ± 1.1	2.9 ± 1.1	2.8 ± 1.1	2.6 ± 1.3	3.9 ± 1.6	3.8 ± 1.6	3.7 ± 1.5	3.2 ± 1.8
Jeong et al[34], 2019	N/A	804	N/A	804	N/A	71.4 ± 10.5	N/A	70.4 ± 10.2	N/A	N/A	N/A	N/A	N/A	3.3 ± 1.8	N/A	3.4 ± 1.8
Lee et al[35], 2019	22177	35965	17745	25420	72.7 ± 10.2	72.0 ± 9.9	70.8 ± 9.9	67.3 ± 12.6	2.75 ± 1.04	2.77 ± 1.02	2.67 ± 1.01	2.58 ± 1.14	3.76 ± 1.41	3.63 ± 1.40	3.55 ± 1.37	3.18 ± 1.61
Cho et al[36], 2019	12502	21000	12593	10409	74.3 ± 8.9	73.8 ± 8.8	72.9 ± 8.9	70.8 ± 11	2.5 ± 0.9	2.5 ± 0.9	2.5 ± 0.9	2.6 ± 1.0	3.7 ± 1.2	3.6 ± 1.2	3.5 ± 1.2	3.5 ± 1.2

HAS-BLED: Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly; War: Warfarin; Dab: Dabigatran; Riv: Rivaroxaban; Api: Apixaban; N/A: Not applicable.